Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Aya A. Negm"'
Autor:
Zuhier A. Awan, Shareefa A. AlGhamdi, Nabil A. Alhakamy, Solomon Z. Okbazghi, Mohamed A. Alfaleh, Shaimaa M. Badr-Eldin, Hibah M. Aldawsari, Mohammed A. S. Abourehab, Hani Z. Asfour, Shadi A. Zakai, Mohammad W. Alrabia, Aya A. Negm, Mohamed A. El-Moselhy, Sara S. Sharkawi, Waleed Y. Rizg
Publikováno v:
Drug Delivery, Vol 29, Iss 1, Pp 1536-1548 (2022)
Certain anticancer agents selectively target the nucleus of cancer cells. One such drug is 2-methoxyestradiol (2ME), which is used for treating lung cancer. To improve the therapeutic effectiveness of these agents, many new methods have been devised.
Externí odkaz:
https://doaj.org/article/ce92aa38c6d1400f8f34cfe349340dab
Autor:
Usama A. Fahmy, Shaimaa M. Badr-Eldin, Osama A. A. Ahmed, Hibah M. Aldawsari, Singkome Tima, Hani Z. Asfour, Mohammed W. Al-Rabia, Aya A. Negm, Muhammad H. Sultan, Osama A. A. Madkhali, Nabil A. Alhakamy
Publikováno v:
Pharmaceutics, Vol 16, Iss 2, p 189 (2024)
This journal retracts the article “Intranasal Niosomal In Situ Gel as a Promising Approach for Enhancing Flibanserin Bioavailability and Brain Delivery: In Vitro Optimization and Ex Vivo/In Vivo Evaluation” [...]
Externí odkaz:
https://doaj.org/article/08231fa9b9684763acc2045a7e8d8c0f
Autor:
Usama A. Fahmy, Shaimaa M. Badr-Eldin, Osama A. A. Ahmed, Hibah M. Aldawsari, Singkome Tima, Hani Z. Asfour, Mohammed W. Al-Rabia, Aya A. Negm, Muhammad H. Sultan, Osama A. A. Madkhali, Nabil A. Alhakamy
Publikováno v:
Pharmaceutics, Vol 12, Iss 6, p 485 (2020)
Flibanserin (FLB) is a multifunctional serotonergic agent that was recently approved by the FDA for the oral treatment of premenopausal women with hypoactive sexual desire disorder. FLB is a centrally acting drug that has a low oral bioavailability o
Externí odkaz:
https://doaj.org/article/9784df45f76740319c3bf62098faf01a
Autor:
Aya A. Negm, Hibah M. Aldawsari
Publikováno v:
Tropical Journal of Pharmaceutical Research. 19:11-15
Purpose: To enhance raloxifene (RLX) delivery and cytotoxicity against breast cancer (MCF-7) cell lines. Methods: This was a solubility study of RLX in different oils, surfactants, and co-surfactants. Twelve formulae were tested to reach the smallest
Autor:
Usama A, Fahmy, Shaimaa M, Badr-Eldin, Osama A A, Ahmed, Hibah M, Aldawsari, Singkome, Tima, Hani Z, Asfour, Mohammed W, Al-Rabia, Aya A, Negm, Muhammad H, Sultan, Osama A A, Madkhali, Nabil A, Alhakamy
Publikováno v:
Pharmaceutics
Flibanserin (FLB) is a multifunctional serotonergic agent that was recently approved by the FDA for the oral treatment of premenopausal women with hypoactive sexual desire disorder. FLB is a centrally acting drug that has a low oral bioavailability o
Autor:
Hibah M. Aldawsari, Nabil A. Alhakamy, Osama Madkhali, Aya A. Negm, Hani Z. Asfour, Mohammed W. Al-Rabia, Muhammad Hadi Sultan, Singkome Tima, Osama A. A. Ahmed, Shaimaa M Badr-Eldin, Usama A. Fahmy
Publikováno v:
Pharmaceutics
Volume 12
Issue 6
Pharmaceutics, Vol 12, Iss 485, p 485 (2020)
Volume 12
Issue 6
Pharmaceutics, Vol 12, Iss 485, p 485 (2020)
Flibanserin (FLB) is a multifunctional serotonergic agent that was recently approved by the FDA for the oral treatment of premenopausal women with hypoactive sexual desire disorder. FLB is a centrally acting drug that has a low oral bioavailability o